Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Beclomethasone/Formoterol in Extra-fine Formulation on Quality of Life and SAD in COPD Patients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* a documented diagnosis of COPD defined according to the guidelines of the American Thoracic Society (ATS) / European Respiratory Society (ERS);~* smokers or former smokers with a smoking history of at least 10 pack / years;~* subjects with a post-bronchodilator forced expiratory volume at the 1st second (FEV1)/ forced vital capacity (FVC) ratio of \< 0.7 and a FEV1 \<50% pred;~* subjects with a high impact of the COPD on their health status (CAT≥10);~* clinical history of at least 1 moderate exacerbation / year;~* COPD patients being treated with BDP/FF NEXThaler® 100/6 μg in extra-fine formulation no more than 1 (one) week before enrollment.~Exclusion Criteria:~* an exacerbation in the four weeks prior to enrollment;~* other coexisting lung diseases (bronchial asthma, restrictive diseases or bronchiectasis) and severe co-morbidities associated with COPD, such as uncontrolled cardiovascular disease, pneumonia or cancer;~* pregnant patients;~* subjects unable to meet the criteria of acceptability and repeatability of pulmonary function tests, according to the ATS / ERS document

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 43 COPD (Type: None): COPD patients with severe airflow obstruction and 1 moderate exacerbation in the previous year being treated with BDP/FF NEXThaler® 100/6 μg b.i.d. for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).